Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Mauna Kea Technologies increases product revenue by 68% in the first quarter of 2026
Mauna Kea Technologies reports Q1 2026 revenue of €1.5m, an increase of 68% on a constant currency basis. Product revenue in the US rose 34% to €1.0m, while international product revenue climbed 326% to €0.5m. Adjusted EBITDA improved by €1.0m in 2025 and total debt was reduced by 69%. The company is targeting EBITDA profitability by the end of 2027; the stock responded with a 1.94% rise. » More on de.investing.com
Financials
| (EUR) | 2024 | YoY |
|---|---|---|
| Revenue | 7.66M | 30.58% |
| Gross profit | 6.44M | 27.71% |
| Net profit | -10.4M | 179.15% |
| EBITDA | -7.97M | 445.31% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €23.09M |
Number of shares | 69.93M |
52-week high/low | €0.33 - €0.33 |
| Dividends | No |
Beta | 1.05 |
P/E ratio | 1.53 |
PEG ratio | 0.00 |
P/B ratio | -2.37 |
P/S ratio | 2.44 |
Company profile
Mauna Kea Technologies SA develops and markets medical devices in Europe, the Middle East, Africa, the United States, Latin America, and Asia. The company designs, develops, and markets tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. Its flagship product is Cellvizio, a confocal miniprobe endomicroscopy system which provides physicians and researchers high-resolution images of tissues at the cellular level. The company was incorporated in 2000 and is headquartered in Paris, France.
| Name | MAUNA KEA TECH |
| CEO | Alexandre Loiseau |
| Headquarters | Paris,
France |
| Website | |
| IPO | 07/06/2011 |
| Employees | 65 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | MKEAF |
Euronext | MKEA.PA |
Frankfurt | 1MK.F |
London | 0P5I.L |
Paris | ALMKT.PA |
München | 1MK.MU |
